Kinney Horn - Olema Pharmaceuticals Chief Officer

OLMA Stock  USD 5.68  0.18  3.27%   

Insider

Kinney Horn is Chief Officer of Olema Pharmaceuticals
Age 50
Phone415 651 3316
Webhttps://olema.com

Kinney Horn Latest Insider Activity

Tracking and analyzing the buying and selling activities of Kinney Horn against Olema Pharmaceuticals stock is an integral part of due diligence when investing in Olema Pharmaceuticals. Kinney Horn insider activity provides valuable insight into whether Olema Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Olema Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Olema Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Olema Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3248) % which means that it has lost $0.3248 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5176) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Olema Pharmaceuticals currently holds 2.42 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Olema Pharmaceuticals has a current ratio of 19.36, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Olema Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

CPA MBAPharvaris BV
63
, MBAMolecular Partners AG
51
CPA MSErasca Inc
55
MD FACPAN2 Therapeutics
77
Eric EasomAN2 Therapeutics
57
Adam LevyZentalis Pharmaceuticals Llc
N/A
Ajim CFAMonte Rosa Therapeutics
47
Peng MDPharvaris BV
47
Carrie MDZentalis Pharmaceuticals Llc
54
Shanna PeekSana Biotechnology
N/A
Michael GaitPepGen
N/A
Thomas TemplemanCentessa Pharmaceuticals PLC
64
Julie CPADesign Therapeutics
N/A
Corinne SavillCullinan Oncology LLC
66
Sanjay ChandaAN2 Therapeutics
60
MBA BSAN2 Therapeutics
49
Aseem AnsariDesign Therapeutics
N/A
Karen AndersonCentessa Pharmaceuticals PLC
57
Sharon TownsonMonte Rosa Therapeutics
50
Wim SouverijnsPharvaris BV
54
David ChaoCentessa Pharmaceuticals PLC
57
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. Olema Pharmaceuticals (OLMA) is traded on NASDAQ Exchange in USA. It is located in 780 Brannan Street, San Francisco, CA, United States, 94103 and employs 74 people. Olema Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Olema Pharmaceuticals Leadership Team

Elected by the shareholders, the Olema Pharmaceuticals' board of directors comprises two types of representatives: Olema Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olema. The board's role is to monitor Olema Pharmaceuticals' management team and ensure that shareholders' interests are well served. Olema Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olema Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
JD Moriarty, Corporate Secretary
Peter Kushner, CoFounder Fellow
PharmD Faltaos, VP Pharmacology
Kinney Horn, Chief Officer
Cyrus Harmon, Chief Director
Courtney Dugan, VP Communications
John Moriarty, Chief VP
Moriarty ESQ, Corporate Secretary
Shane MBA, Chief Officer
Julie Dexter, Senior People
Courtney OKonek, Vice Communications
Naseem MD, Chief Officer
David Myles, Chief Officer
Geoffrey Mogilner, Vice Communications
Sasha CPA, VP Controller

Olema Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Olema Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.